Loading company…
Nexo Therapeutics develops drugs targeting proteins associated with cancer.
Nexo Therapeutics develops medicines aimed at cancer-associated proteins that have been difficult to target. Its CODON platform combines chemical diversity, covalent chemistry, and biochemical and in-cell proteomics. Founded in 2022, the company is based in Colorado, US. In July 2023, it raised USD 60 million in Series A funding led by Versant Ventures, with New Enterprise Associates and Cormorant Asset Management participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in